News25/Ratings12
News · 26 weeks76+14%
2026-04-192026-10-11
Mix3390d
- Insider17(52%)
- SEC Filings6(18%)
- Analyst3(9%)
- Earnings3(9%)
- Other2(6%)
- Offering2(6%)
Latest news
25 items- INSIDERSEC Form 4 filed by Q32 Bio Inc.4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Q32 Bio Inc.4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Q32 Bio Inc.4 - Q32 Bio Inc. (0001661998) (Issuer)
- ANALYSTLeerink Partners initiated coverage on Q32 Bio with a new price targetLeerink Partners initiated coverage of Q32 Bio with a rating of Outperform and set a new price target of $40.00
- SECQ32 Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Q32 Bio Inc. (0001661998) (Filer)
- PRQ32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026-- Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 ---- Robust durability, including maintenance and deepening of response, observed following the 16-week off-drug period supporting potential for less frequent, chronic maintenance dosing -- -- Mechanism of action supported by biomarker results and biopsy findings ---- Generally well-tolerated safety profile, consistent with prior studies, with no new safety signals ---- Data supports further development of bempikibart as a chronic treatment in alopecia areata; Q32 Bio intends to advance a registration-directed program in the first half of 2027 --WALTHAM, Mass., Sept. 30, 2026 /PRNewswire/ -- Q32
- ANALYSTJefferies initiated coverage on Q32 Bio with a new price targetJefferies initiated coverage of Q32 Bio with a rating of Buy and set a new price target of $29.00
- PRQ32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026-- Late-breaking oral and poster presentations to feature additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata --WALTHAM, Mass., Sept. 21, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA will be featured
- SECQ32 Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Q32 Bio Inc. (0001661998) (Filer)
- PRQ32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer-- Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage clinical development ---- Dr. Hershberger is a drug development leader with over 30 years of experience spanning late-stage development operations and regulatory strategy --WALTHAM, Mass., Sept. 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced the appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Offic
- PRQ32 Bio to Participate in Upcoming September Investor ConferencesWALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that management will participate in three upcoming investor conferences in September:Wells Fargo 21st Annual Healthcare ConferenceDate: Tuesday, September 8, 2026Fireside Chat Presentation Time: 3:45 p.m. E.T.Location: Boston, MACantor Global Healthcare Conference 2026Date: Wednesday, September 9, 2026Fireside Chat Presentation Time: 3:55 p.m. E.T.Location: New York, NYMorgan Stanley 24th Annual Global Healthcare ConferenceDate: Tuesday,
- INSIDERCFO and President Kalowski Lee sold $65,776 worth of shares (3,972 units at $16.56), decreasing direct ownership by 3% to 138,471 units (SEC Form 4) (withholding obligation)4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERCEO Morrison Jodie Pope sold $163,033 worth of shares (9,845 units at $16.56), decreasing direct ownership by 3% to 343,259 units (SEC Form 4) to satisfy tax liability4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERChief Scientific Officer Violette Shelia M. sold $46,335 worth of shares (2,798 units at $16.56), decreasing direct ownership by 2% to 127,771 units (SEC Form 4) (for tax liability)4 - Q32 Bio Inc. (0001661998) (Issuer)
- ANALYSTMorgan Stanley initiated coverage on Q32 Bio with a new price targetMorgan Stanley initiated coverage of Q32 Bio with a rating of Overweight and set a new price target of $34.00
- SECSEC Form 10-Q filed by Q32 Bio Inc.10-Q - Q32 Bio Inc. (0001661998) (Filer)
- SECQ32 Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Q32 Bio Inc. (0001661998) (Filer)
- PRQ32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update-- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a medical conference in the second half of 2026 ---- Patient enrollment and dosing in SIGNAL-AA Part B open-label extension (OLE) ongoing ---- Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in 1H'2027 subject to planned regulatory discussions later this year ---- Half-life extended fully human anti-IL-7Rα antibody, ADX-914-XL, advancing in pre-clinical development ---- Completed $200 million public offering in July 2026 ---- Cas
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Q32 Bio Inc.SCHEDULE 13G/A - Q32 Bio Inc. (0001661998) (Subject)
- SECSEC Form EFFECT filed by Q32 Bio Inc.EFFECT - Q32 Bio Inc. (0001661998) (Filer)
- SECSEC Form 424B3 filed by Q32 Bio Inc.424B3 - Q32 Bio Inc. (0001661998) (Filer)
- INSIDERAmendment: SEC Form 4 filed by Director Tzianabos Arthur4/A - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Laporte Kathleen4/A - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Lundberg Sven Ante4/A - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Iwicki Mark T4/A - Q32 Bio Inc. (0001661998) (Issuer)
QTTB FAQ
6 questionsWhere does QTTB stock trade?
Q32 Bio Inc. (QTTB) is listed on NASDAQ.What sector and industry is QTTB in?
Q32 Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Q32 Bio Inc. go public?
Q32 Bio Inc. (QTTB) completed its IPO in 2018.What are analysts saying about QTTB?
Q32 Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $4000.00 price target on 2026-10-12.What companies are similar to QTTB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare QTTB side-by-side with any of them on Quantisnow.How can I track QTTB on Quantisnow?
Quantisnow aggregates Q32 Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QTTB to receive live email and push alerts on every new disclosure.